What is prognosis of Lung cancer?

Dhageyso boggan

Waa maxay saadaasha kansarka sanbabada?

saadaasha kansarka sanbabada waxay ku xiran tahay dhowr arrimood, oo ay ku jiraan marxaladda kansarka, nooca kansarka sanbabada, iyo caafimaadka guud ee bukaanka.

Kansarka sanbabada ee unugyada aan yarayn, oo ah nooca ugu badan, wuxuu leeyahay heerka noolaanshaha 5-sano ee qiyaastii 18% dhammaan marxaladaha oo la isku daray.

Si kastaba ha noqotee, haddii kansarka la helo goor hore, heerka noolaanshaha 5-sano wuxuu noqon karaa 57%. Kansarka sanbabada ee unugyada yaryar, oo aan caadi ahayn, wuxuu leeyahay heerka noolaanshaha 5-sano oo ah qiyaastii 7% dhammaan marxaladaha oo la isku daray.

Waxaa muhiim ah in la ogaado in kuwani ay yihiin tirakoob guud oo natiijooyinka shaqsiyadeed ay kala duwanaan karaan.

Xulashada daaweynta iyo horumarka daawada ayaa sii kordhaya, bukaan badanina waxay noolaan karaan waqti dheer waxayna leeyihiin nolol tayo leh oo leh daryeel iyo maareyn habboon.

Tixraacyada

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Martini B: [Lung cancer--epidemiology, prognosis and therapy]. Med Monatsschr Pharm. 2006, 29 (6): 217-21.

Zou T, Liu JY, She L, Yin JY, Li X, Li XP, Zhou HH, Chen J, Liu ZQ: The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Front Pharmacol. 2020, 11 (): 1029.

Li L, Zhou Q, Luo D, Xu Y, Yang H, Zhang S, Li A, Li H, Lv C: [A study on the relationship between lung cancer cell apoptosis and prognosis in patients with human non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 1998, 1 (2): 70-3.

Feng YY, Yang Y, Wang YY, Bai XX, Hai P, Zhao R: [Hypomethylation of DAPL1 associated with prognosis of lung cancer patients with EGFR Del19 mutation]. Zhonghua Zhong Liu Za Zhi. 2021, 43 (12): 1264-1268.

Xiao Y, Zhu S, Yin W, Liu X, Hu Y: IGFBP-4 expression is adversely associated with lung cancer prognosis. Oncol Lett. 2017, 14 (6): 6876-6880.

Lang J, Zhao Q, He Y, Yu X: Bone turnover markers and novel biomarkers in lung cancer bone metastases. Biomarkers. 2018, 23 (6): 518-526.

Diidmada masuuliyada: caafimaadka

Boggan waxaa loogu talagalay ujeedooyin waxbarasho iyo macluumaad oo keliya mana aha bixinta talo caafimaad ama adeegyo xirfadeed.

Macluumaadka la bixiyo waa in aan loo isticmaalin in lagu ogaado ama lagu daweeyo dhibaato caafimaad ama cudur, kuwa raadinaya talo caafimaad oo shaqsiyeed waa inay la tashadaan dhakhtar ruqsad haysta.

Fadlan la soco in shabakada neerfaha ee soo saarta jawaabaha su'aalaha, ay tahay mid aan sax ahayn marka ay timaado waxyaabaha tirooyinka ah. Tusaale ahaan, tirada dadka la ogaaday inay qabaan cudur gaar ah.

Had iyo jeer raadi talada dhakhtarkaaga ama daryeel caafimaad oo kale oo u qalma oo ku saabsan xaalad caafimaad. Waligaa ha iska indho tirin talada caafimaadka xirfadeed ama ha dib u dhigin raadinta sababtoo ah wax aad ka akhrisay boggan internetka. Haddii aad u maleyneyso inaad leedahay xaalad caafimaad oo degdeg ah, wac 911 ama u tag qolka gurmadka degdegga ah ee kuugu dhow isla markiiba. Xiriirka dhakhtarka iyo bukaanka looma abuuro boggan internetka ama isticmaalkiisa. BioMedLib ama shaqaalaheeda, ama qof kasta oo ka qaybqaata boggan internetka, ma sameeyaan wax matalaad ah, si cad ama si macquul ah, oo ku saabsan macluumaadka halkan lagu bixiyo ama isticmaalkiisa.

Ogaysiiska: Xuquuqda daabacaadda

Sharciga Xuquuqda daabacaadda ee Digital Millennium ee 1998, 17 U.S.C. § 512 (the DMCA) wuxuu bixiyaa gurmad milkiilayaasha xuquuqda daabacaadda ee aaminsan in waxyaabaha ka muuqda Internetka ay ku xadgudbayaan xuquuqdooda sharciga xuquuqda daabacaadda ee Mareykanka.

Haddii aad si wanaagsan u aaminsan tahay in wax ka mid ah waxyaabaha ku jira boggeena internetka ama adeegyadeena ay ku xadgudbayaan xuquuqdaada daabacaadda, adiga (ama wakiilkaaga) ayaa noo soo diri kara ogeysiis codsanaya in waxyaabaha ku jira ama waxyaabaha laga saaro, ama la xakameeyo helitaanka.

Ogeysiisyada waa in lagu diraa qoraal ahaan emayl (eeg qaybta "Contact" ee cinwaanka emaylka).

DMCA waxay u baahan tahay in ogeysiiskaaga ku saabsan xadgudubka xuquuqda daabacaadda ee la sheegay uu ku jiro macluumaadka soo socda: (1) sharaxaadda shaqada xuquuqda daabacaadda ee ay ku saabsan tahay xadgudubka la sheegay; (2) sharaxaadda nuxurka xadgudubka la sheegay iyo macluumaadka ku filan ee noo oggolaanaya inaan helno nuxurka; (3) macluumaadkaaga xiriirka adiga, oo ay ku jiraan cinwaankaaga, lambarka taleefanka iyo cinwaanka emaylkaaga; (4) bayaan aad ku leedahay aaminaad wanaagsan oo ah in nuxurka habka lagu cabiray uusan oggolaan milkiilaha xuquuqda daabacaadda, ama wakiilkiisa, ama hawlgalka sharci kasta;

(5) bayaan aad saxiixday oo aad ku cadeyneyso in macluumaadka ku jira ogeysiiska uu sax yahay iyo in aad awood u leedahay in aad dhaqan geliso xuquuqda daabacaadda ee la sheeganayo in la jabiyay;

iyo (6) saxiix jireed ama elektaroonig ah oo ka yimid milkiilaha xuquuqda daabacaadda ama qof loo oggol yahay inuu ku dhaqmo magaca milkiilaha xuquuqda daabacaadda.

Haddii aadan ku darin dhammaan macluumaadka kor ku xusan waxay keeni kartaa dib u dhac ku yimaada ka baaraandegista cabashadaada.

Xiriirka

Fadlan noogu soo dir emayl su'aal kasta / soo jeedin.

What is prognosis of lung cancer?

The prognosis of lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the overall health of the patient.

Non-small cell lung cancer, which is the most common type, has a 5-year survival rate of about 18% for all stages combined.

However, if the cancer is caught early, the 5-year survival rate can be as high as 57%. Small cell lung cancer, which is less common, has a 5-year survival rate of about 7% for all stages combined.

It is important to note that these are general statistics and individual outcomes may vary.

Treatment options and advancements in medicine continue to improve, and many patients can live longer and have a better quality of life with proper care and management.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.